OncoMatch/Clinical Trials/NCT05732831
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Is NCT05732831 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including TNG462 and Pembrolizumab for locally advanced solid tumor.
Treatment: TNG462 · Pembrolizumab — This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: MTAP absence of protein
Required: MTAP bi-allelic (homozygous) deletion
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate organ function/reserve per local labs
Kidney function
adequate renal function per local labs
Liver function
adequate liver function per local labs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Palo Alto, California
- Grand Valley Oncology · Grand Junction, Colorado
- Florida Cancer Specialists & Research Institute · Lake Mary, Florida
- Sylvester Comprehensive Cancer Center · Miami, Florida
- University Chicago Medicine · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify